The role of salt in the pathology of mineralocorticoid receptor mediated cardiovascular inflammation and fibrosis

被引：0
|
作者：
Lam, E. Y. M. [1 ]
Fuller, P. J. [1 ]
Morgan, J. [1 ]
Funder, J. W. [1 ]
Young, M. J. [1 ]
机构：
[1] Prince Henrys Inst, Melbourne, Vic, Australia
来源：
HYPERTENSION | 2007年 / 49卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：1470 / 1470
页数：1
相关论文
共 50 条
  • [21] The main target for inhibiting mineralocorticoid receptor-mediated signaling in cardiovascular diseases
    Kazuhiro Yamamoto
    Hypertension Research, 2013, 36 : 580 - 582
  • [22] The main target for inhibiting mineralocorticoid receptor-mediated signaling in cardiovascular diseases
    Yamamoto, Kazuhiro
    HYPERTENSION RESEARCH, 2013, 36 (07) : 580 - 582
  • [23] Mineralocorticoid receptor antagonists and glucocorticoids differentially affect skeletal muscle inflammation and pathology in muscular dystrophy
    Howard, Zachary M.
    Gomatam, Chetan K.
    Rabolli, Charles P.
    Lowe, Jeovanna
    Piepho, Arden B.
    Bansal, Shyam S.
    Accornero, Federica
    Rafael-Fortney, Jill A.
    JCI INSIGHT, 2022, 7 (19)
  • [24] Mineralocorticoid Receptor Blocker Prevents Mineralocorticoid Receptor-Mediated Inflammation by Modulating Transcriptional Activity of Mineralocorticoid Receptor-p65-Signal Transducer and Activator of Transcription 3 Complex
    Kuyama, Naoto
    Araki, Satoshi
    Kaikita, Koichi
    Nakanishi, Nobuhiro
    Nakashima, Naoya
    Hanatani, Shinsuke
    Arima, Yuichiro
    Yamamoto, Masahiro
    Nakamura, Taishi
    Yamamoto, Eiichiro
    Matsushita, Kenichi
    Matsui, Kunihiko
    Tsujita, Kenichi
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (18):
  • [25] Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension
    Klanke, Bernd
    Cordasic, Nada
    Hartner, Andrea
    Schmieder, Roland E.
    Veelken, Roland
    Hilgers, Karl F.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (11) : 3456 - 3463
  • [26] Targeting the mineralocorticoid receptor in cardiovascular disease
    Young, Morag J.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (03) : 321 - 331
  • [27] Mineralocorticoid Receptor Antagonists Attenuate Pulmonary Inflammation And Bleomycin-Elicited Fibrosis In The Rat And Mouse
    Jimenez, J.
    Fernandez, X.
    Mingo, G. G.
    Jia, Y.
    Lieber, G. B.
    Crawley, Y.
    Anthes, J. C.
    McLeod, R. L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [28] Mineralocorticoid receptor antagonists attenuate pulmonary inflammation and bleomycin-evoked fibrosis in rodent models
    Lieber, Gissela B.
    Fernandez, Xiomara
    Mingo, Garfield G.
    Jia, Yanlin
    Caniga, Michael
    Gil, Malgorzata A.
    Keshwani, Shanil
    Woodhouse, Janice D.
    Cicmil, Milenko
    Moy, Lily Y.
    Kelly, Nancy
    Jimenez, Johanna
    Crawley, Yvette
    Anthes, John C.
    Klappenbach, Joel
    Ma, Yu-Lu
    McLeod, Robbie L.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 718 (1-3) : 290 - 298
  • [29] Sex differences in the role of the smooth muscle cell mineralocorticoid receptor in cardiovascular aging
    DuPont, Jennifer J.
    Kim, Seung K.
    Sun, Zhe
    Aronovitz, Mark J.
    Baur, Wendy E.
    Meininger, Gerald A.
    Hill, Michael A.
    Jaffe, Iris Z.
    FASEB JOURNAL, 2018, 32 (01):
  • [30] Aldosterone, Mineralocorticoid Receptor and the Metabolic Syndrome: Role of the Mineralocorticoid Receptor Antagonists
    Ronconi, Vanessa
    Turchi, Federica
    Appolloni, Gloria
    di Tizio, Valentina
    Boscaro, Marco
    Giacchetti, Gilberta
    CURRENT VASCULAR PHARMACOLOGY, 2012, 10 (02) : 238 - 246
12345